You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Smartphone Technology for Parents and Teens: Improving Vaccination Uptake
SBC: KLEIN BUENDEL, INC. Topic: NICHDDESCRIPTION provided by applicant Vaccinations for adolescents in the U S tetanus diphtheria and acellular pertussis Tdap meningococcal conjugate vaccine MCV Human Papillomavirus HPV vaccines Gardasil and Cervarex remain well below the Centers for Disease Control and Prevention CDC goals and especially so for the HPV vaccines These vaccine deficits are pronounced among minor ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
High-specificity affinity reagents for the detection of glycan sialylation
SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC Topic: 300DESCRIPTION provided by applicant Glycans have several distinct properties that make their development as disease biomarkers appealing Firstly their location on cell surfaces makes them the first point of contact for cellular interactions and thus they are crucial in the control of normal metabolic processes and conversely they function as pathogen adhesion receptors Secondly specific gl ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of Isotopically Labeled Glycoproteins for use as Internal Standards
SBC: GLYCOSCIENTIFIC, L.L.C. Topic: 300DESCRIPTION provided by applicant The ability to accurately quantitate the glycan chains attached to glycoproteins has wide ranging implications Numerous studies over the past years have demonstrated that abnormal glycosylation occurs in virtually all types of human cancers and demonstrate the potential of using glycan markers in either a diagnostic or a prognostic manner The glycosylatio ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Scientific Merit and Feasibility of Fructokinase Inhibiton for Obesity
SBC: COLORADO RESEARCH PARTNERS LLC Topic: NIDDKDESCRIPTION provided by applicant Intake of added sweeteners high fructose corn syrup and sucrose independently predicts the development of obesity metabolic syndrome and diabetes Despite recommendations by WHO and the AHA to reduce sugar intake to to percent of total energy intake the mean intake of added sugars remains percent of the diet and percent of the population ingest ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Manufacturing pathogen inactivated platelet lysate to treat corneal inflammation
SBC: Cambium Medical Technologies LLC Topic: NDESCRIPTION provided by applicant Ocular graft versus host disease O GVHD is a particularly severe and debilitating complication of allogeneic hematopoietic stem cell transplantation HSCT O GVHD develops in of patients with chronic GVHD Currently Restasis cyclosporine A is the only FDA approved prescription topical medication to treat O GVHD In Restasis had sales o ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Anti-CXCL13 mAb to mitigate prostate cancer health disparities
SBC: JYANT Technologies, Inc. Topic: NIMHDDESCRIPTION provided by applicant The most common metastatic site for hormone refractory prostate cancer HRPC PCa is bone While docetaxel can prolong the overall survival in patients with metastatic HRPC current treatments do not provide a cure Further complicating the matter HRPC is a disease that affects a variety of patients differently which can be problematic for physicians to prov ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Novel adjuvant therapy for triple negative breast cancer
SBC: JYANT Technologies, Inc. Topic: 102DESCRIPTION provided by applicant Triple negative breast cancer TNBC is very difficult to treat and has no specific targeted therapies Chemotherapies used to treat this disease have many undesirable side effects and patients eventually relapse as a result of chemoresistance Obesity is pandemic in the US and many TNBC suffer from this as well Obesity is accompanied by high levels of leptin ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A Dietary Supplement As Adjunct Therapy In Castration-Resistant Prostate Cancer
SBC: MetCure Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Castration Resistant Prostate Cancer Castration resistant prostate cancer CRPC directly contributes to patient mortality It is imperative to develop new and effective adjunct therapy to enhance the response of CRPC to hormonal therapy Recently we developed ProFineTM a proprietary formula consisting of bioactive flavonoids enriched in pomegranate fruit and ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Enhancing Care of the Aged and Dying in Prisons
SBC: KLEIN BUENDEL, INC. Topic: NIADESCRIPTION provided by applicant The United States has the highest rate of incarceration in the world The demographics of the prison population are shifting In fact the number of sentenced state and federal prisoners age or older grew at times the rate of the overall prison population from The health status of aging inmates does not mirror the free world population In fac ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
NMDA Receptor Subtype Selective Modualtors as Alzheimer's Disease Therapeutics
SBC: NEUROP, INC. Topic: NIADESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a devastating neurodegenerative disorder. One of the few drugs used to treat AD is memantine, which inhibits N-methyl-d-aspartate receptors (NMDARs), glutamate receptor subtypes found at nearly all vertebrate excitatory synapses. NMDARs are critically involved in many aspects of nervous system function, including learning and me ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health